Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYOTONACHOL vs OCUSERT PILO-40
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.
FDA-approved: Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder.,Off-label: Treatment of gastroesophageal reflux disease; management of chronic intestinal pseudo-obstruction; treatment of xerostomia (dry mouth) in Sjögren's syndrome or radiation-induced.
Open-angle glaucoma,Ocular hypertension,Angle-closure glaucoma (emergency treatment),Induction of miosis during ophthalmic surgery,Off-label: Diagnostic miosis
25 mg orally three times daily. Maximum dose 100 mg four times daily.
One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Terminal elimination half-life is approximately 1-2 hours; clinical effect duration is extended due to the sustained-release delivery system.
Bethanechol is primarily metabolized via hydrolysis by plasma esterases (pseudocholinesterases) to inactive metabolites. Minimal hepatic metabolism occurs.
Primarily metabolized by plasma esterases via hydrolysis, with minor hepatic metabolism (CYP450 not significantly involved).
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Primarily renal (80-90% as unchanged drug and inactive metabolites); biliary/fecal excretion accounts for <5%.
~30%, bound primarily to albumin.
Binding to plasma proteins is negligible (<10%); primarily bound to tissue proteins in the eye.
0.3-0.6 L/kg, indicating distribution into total body water.
0.3-0.6 L/kg in systemic circulation; local ocular distribution is extensive but systemic Vd is low.
Oral: 10-20% (extensive first-pass metabolism); Subcutaneous: ~80%; Intravenous: 100%.
Systemic bioavailability is minimal (<1%) due to local ocular administration and first-pass hydrolysis; virtually 100% of the released dose is available locally in the eye.
GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: not recommended.
No specific adjustment required; pilocarpine is primarily metabolized in the eye and systemic absorption minimal. GFR not relevant.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily. Child-Pugh C: not recommended.
No specific adjustment required; pilocarpine undergoes minimal hepatic metabolism. Child-Pugh not applicable.
0.5-1 mg/kg orally three times daily; maximum 25 mg per dose.
Not established; safety and efficacy in pediatric patients not determined. Use only if clearly needed.
Start at 25 mg twice daily due to increased anticholinergic sensitivity.
No specific dose adjustment; consider potential increased risk of systemic effects due to reduced tear production or conjunctival changes. Monitor for bradycardia, hypotension, or bronchospasm.
None
No FDA black box warning.
May cause reflex tachycardia due to hypotension; caution in patients with coronary artery disease, bradycardia, or recent myocardial infarction. Increased vagal tone may precipitate asthma attacks; avoid in asthmatics. May cause exacerbation of peptic ulcer disease. Can increase ureteral pressure; avoid in ureteral obstruction. Use cautiously in patients with epilepsy or hyperthyroidism. Monitor for cholinergic crisis (salivation, lacrimation, urination, defecation, emesis).
Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia,May cause transient or permanent miosis leading to reduced vision in low light,Ciliary spasm, headache, and brow ache,Potential for systemic absorption causing bradycardia, hypotension, and bronchospasm,Caution in patients with asthma, bradycardia, or hypotension
Absolute: Hypersensitivity to bethanechol; mechanical obstruction of the gastrointestinal or urinary tract; recent gastrointestinal anastomosis or bladder surgery; hyperthyroidism; peptic ulcer disease; asthma; epilepsy; Parkinsonism; hypotension; bradycardia; coronary artery disease. Relative: Pregnancy (C); nursing mothers; patients with vagotonia or receiving quinidine or procainamide.
Hypersensitivity to pilocarpine or any component,Patients with acute inflammatory disease of the eye (e.g., iritis, uveitis),Uncontrolled asthma or severe bradycardia (systemic effects)
Food decreases absorption; take on an empty stomach. Avoid high-fat meals as they may increase side effects. No known specific food interactions.
No significant food interactions known. Maintain adequate fluid intake. Avoid alcohol, which may increase risk of side effects like dizziness or blurred vision.
Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies. Second trimester: Potential for premature labor due to cholinergic stimulation. Third trimester: Increased risk of uterine hyperstimulation and fetal distress if used for labor induction. Avoid use during pregnancy unless clearly needed.
Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and third trimesters, use may cause fetal bradycardia and hypotension. The benefit must justify the potential risk.
Excreted in human milk in low concentrations. M/P ratio not established. Caution advised. Potential for cholinergic adverse effects in the infant (e.g., diarrhea, increased secretions). Use only if benefit outweighs risk.
Pilocarpine is excreted into breast milk. The M/P ratio is not established. Due to potential for systemic absorption in the infant, use while breastfeeding is not recommended. Monitor infant for cholinergic effects.
No standard dose adjustments recommended due to limited pharmacokinetic data in pregnancy. However, increased plasma volume and renal clearance may necessitate dose titration based on clinical response. Use lowest effective dose and monitor for maternal cholinergic toxicity.
Pregnancy may alter the pharmacokinetics of pilocarpine due to increased plasma volume and enhanced metabolic clearance. However, specific dose adjustment guidelines are not established. Titrate to the lowest effective dose to control intraocular pressure and monitor for systemic effects.
MYOTONACHOL (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for bradycardia and bronchospasm, especially in patients with asthma or cardiac disease. Administer on an empty stomach to reduce nausea. Avoid use in patients with GI obstruction or recent bladder surgery. Atropine should be readily available as an antidote.
Ocusert Pilo-40 is a sustained-release ocular insert delivering pilocarpine 40 mcg/hr for 7 days. Instruct patient to insert into conjunctival cul-de-sac at bedtime to minimize initial blurring and brow ache. Monitor for signs of retinal detachment, especially in myopic patients. Contraindicated in acute iritis, shallow anterior chamber, and narrow-angle glaucoma (can worsen angle closure). Use with caution in patients with corneal abrasions or ulcers. Systemic absorption can cause bradycardia, hypotension, and increased GI motility.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Avoid alcohol and caffeine, as they may worsen side effects.,Report symptoms like slow heart rate, wheezing, dizziness, or excessive sweating.,Do not drive or operate heavy machinery until you know how this drug affects you.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.
Wash hands before handling the insert. Do not touch the eye with the insert.,Insert the oval-shaped Ocusert into the lower conjunctival sac at bedtime; it should not be felt after placement.,The insert works for 7 days; replace with a new one weekly. Remove at the end of the week and discard.,Do not wear contact lenses with Ocusert in place. Remove lenses before insertion and wait 15 minutes before reinserting after removal.,Expect temporary blurred vision and brow ache for the first few hours to days; these side effects often decrease with continued use.,If the insert falls out, rinse it with cool tap water and reinsert quickly. If lost or damaged, use a new one.,Report severe eye pain, vision changes, or redness immediately.,Avoid driving or operating machinery until you know how this medication affects your vision.,Keep out of reach of children; do not use after expiration date.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYOTONACHOL vs OCUSERT PILO-40, answered by our medical review team.
MYOTONACHOL is a Cholinergic Agonist that works by Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.. OCUSERT PILO-40 is a Ophthalmic Cholinergic Agonist that works by Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYOTONACHOL and OCUSERT PILO-40 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYOTONACHOL is: 25 mg orally three times daily. Maximum dose 100 mg four times daily.. The standard adult dose of OCUSERT PILO-40 is: One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYOTONACHOL and OCUSERT PILO-40 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYOTONACHOL is classified as Category C. Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies.. OCUSERT PILO-40 is classified as Category C. Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.